Age-dependent changes in the putamen transcriptome and proteome of a transgenic minipig model of Huntington's disease

Huntington's disease is an inherited neurodegenerative disorder with no disease-modifying treatment available. Preclinical trials of gene therapies rely on large animal models and the transgenic Huntington's disease (TgHD) minipig is one of them. Minipigs live more than a decade, so the effect of a single dose of gene therapy can be followed for years. The TgHD transgene carries a mixed CAG/CAA repeat that is not expected to expand somatically. However, its putamen, part of the striatum that degenerates first in patients, had not been examined by genome-wide methods, nor beyond 4 years of age. We compared the putamen of transgenic and wild-type minipigs at 4 and 8 years by RNA sequencing and label-free mass spectrometry proteomics, and measured mutant huntingtin by immunoassay. Seven genes were differentially expressed at 4 years and 3,324 at 8 years, and the pathway changes of the transcriptome and the proteome were concordant at that age. The D2 medium spiny neuron marker gene set was reduced at 8 years in both the transcriptome and the proteome. Mitochondrial and oxidative phosphorylation pathways were positively enriched at 4 years and negatively enriched at 8 years. Immune and complement pathways were positively enriched at 8 years, and the number of altered splicing events increased almost fivefold between 4 and 8 years. We detected no age-dependent accumulation of soluble mutant huntingtin. Since the repeat does not expand, these changes developed without somatic expansion, a major driver of progression in human Huntington's disease. We propose that the reduced neuronal markers reflect a loss of neuronal identity rather than neuronal death. The TgHD minipig would then recapitulate the slow early phase of the disease, when treatment is arguably most likely to help.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.766462
Primary Topic
Genetic Neurodegenerative Diseases
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Age-dependent changes in the putamen transcriptome and proteome of a transgenic minipig model of Huntington's disease

Petr Vodička, Jiřı́ Klı́ma, Ivona Valeková, Jana Juhásová et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Genetic Neurodegenerative Diseases
preprint

Age-dependent changes in the putamen transcriptome and proteome of a transgenic minipig model of Huntington's disease

Petr Vodička, Jiřı́ Klı́ma, Ivona Valeková, Jana Juhásová, Eva Kamenná, Georgina F Osborne, Dávid Sekáč, Jakub Červenka, Zdeňka Ellederová, Christian Landles, Helena Kupcová Skalníková, Štefan Juhás, Jiří Klempíř, Kateryna Nemesh, Jan Motlík, Kolesnikova Anastasiia
preprint en

Abstract

Huntington's disease is an inherited neurodegenerative disorder with no disease-modifying treatment available. Preclinical trials of gene therapies rely on large animal models and the transgenic Huntington's disease (TgHD) minipig is one of them. Minipigs live more than a decade, so the effect of a single dose of gene therapy can be followed for years. The TgHD transgene carries a mixed CAG/CAA repeat that is not expected to expand somatically. However, its putamen, part of the striatum that degenerates first in patients, had not been examined by genome-wide methods, nor beyond 4 years of age. We compared the putamen of transgenic and wild-type minipigs at 4 and 8 years by RNA sequencing and label-free mass spectrometry proteomics, and measured mutant huntingtin by immunoassay. Seven genes were differentially expressed at 4 years and 3,324 at 8 years, and the pathway changes of the transcriptome and the proteome were concordant at that age. The D2 medium spiny neuron marker gene set was reduced at 8 years in both the transcriptome and the proteome. Mitochondrial and oxidative phosphorylation pathways were positively enriched at 4 years and negatively enriched at 8 years. Immune and complement pathways were positively enriched at 8 years, and the number of altered splicing events increased almost fivefold between 4 and 8 years. We detected no age-dependent accumulation of soluble mutant huntingtin. Since the repeat does not expand, these changes developed without somatic expansion, a major driver of progression in human Huntington's disease. We propose that the reduced neuronal markers reflect a loss of neuronal identity rather than neuronal death. The TgHD minipig would then recapitulate the slow early phase of the disease, when treatment is arguably most likely to help.

bioRxiv (Cold Spring Harbor Laboratory)
Czech Academy of Sciences (CZ), Charles University (CZ), Czech Academy of Sciences, Institute of Animal Physiology and Genetics (CZ), Institute of Animal Physiology of the Slovak Academy of Sciences (SK), University College London (GB)
CHDI Foundation, European Federation of Pharmaceutical Industries and Associations, University College London, European Commission, Ministerstvo Zdravotnictví Ceské Republiky, Akademie Věd České Republiky, HORIZON EUROPE Framework Programme
Good health and well-being
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon